Results for "antiviral"
Antiviral activity of S/GSK1349572, the only once-daily, unboosted integrase inhibitor in clinical development, evaluated in phase 2 study
First published: 20 July 2009
Shionogi-GlaxoSmithKline Pharmaceuticals, LLC announced today results from a Phase 2a study evaluating antiviral activity of its investigational integrase inhibitor (INI), S/GSK1349572. The results...
Antiviral Activity of S/GSK1265744, a Once-Daily, Unboosted Integrase Inhibitor in Clinical Development, Evaluated in Phase 1-2a Study in Healthy and HIV-Infected Subjects
First published: 13 September 2009
Shionogi-GlaxoSmithKline Pharmaceuticals, LLC announced today results from a Phase 1-2a study evaluating the pharmacokinetics (PK), safety and antiviral activity of its investigational integrase in...
ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV
First published: 09 March 2021
Maturation inhibitors are a class of antiretroviral medicines that target the late stage of the HIV viral life cycle.
GSK receives marketing authorisation from the European Commission for additional Revolade™
First published: 24 September 2013
GSK announced today that the European Commission has granted an additional indication for Revolade™ (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with ch...
The UK Government signs influenza pandemic contract with GlaxoSmithKline for Relenza®
First published: 28 January 2009
The UK is now one of the world’s leading countries in stockpiling antivirals for treating infected individuals in the event of an influenza pandemic
GSK receives positive CHMP opinion for REVOLADE in thrombocytopenia associated with chronic hepatitis C infection
First published: 26 July 2013
GSK announced a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorisation for Revolade™ (eltrombopag).
First published: 08 July 2021
ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months
First published: 22 August 2019
ATLAS-2M study met its primary endpoint, showing similar efficacy of cabotegravir and rilpivirine administered every eight weeks compared to four-week administration.
Shionogi-ViiV Healthcare announces initial data from pivotal phase III study of dolutegravir in HIV
First published: 02 April 2012
SPRING-2 study meets primary endpoint of non-inferiority of dolutegravir compared to raltegravir over 48 weeks in treatment-naïve HIV patients.
ViiV Healthcare starts third phase III HIV treatment study investigating long-acting two-drug regimen of cabotegravir plus rilpivirine
First published: 27 November 2017
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced the start of a phase III study with a two-drug regimen of ...